How a venom clue led to a blood-pressure medicine
In the 1960s, researchers studying the venom of the Brazilian pit viper Bothrops jararaca found small molecules that prolonged the action of bradykinin, a substance that widens blood vessels and can lower blood pressure. The finding pointed to an enzyme that normally helps break bradykinin down—and also plays a role in raising pressure.
That enzyme, angiotensin-converting enzyme, or ACE, helps make angiotensin II, a chemical that narrows blood vessels. Blocking ACE therefore has a two-sided effect: less vessel-narrowing angiotensin II is produced, and more bradykinin can remain active. Blood vessels relax, easing the pressure blood exerts against their walls.
From venom peptide to a usable drug
The venom molecules were a biological clue, not a medicine ready to give patients. Researchers worked out how the peptides interfered with ACE and used that understanding to design drugs that could do the job more practically. The result was captopril, the first widely used ACE inhibitor, introduced in the early 1980s.
Captopril is not made from snake venom. It is a small, manufactured molecule that blocks ACE. Later ACE inhibitors built on the same approach. The development shows how a toxin can reveal a useful target in the body: the therapeutic idea came from understanding what the venom changed, while the medicine itself was engineered for treatment rather than borrowed from the snake.
